NCT00286780View on ClinicalTrials.gov

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

AT-101

80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks

Trial Locations (1)

92093

UCSD Moores Cancer Center, San Diego

Sponsors
All Listed Sponsors
lead

Ascenta Therapeutics

INDUSTRY

NCT00286780 - Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter